Do we need dosimetry for optimization of theranostics in CNS tumors?

Détails

ID Serval
serval:BIB_1A384EB288EC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Do we need dosimetry for optimization of theranostics in CNS tumors?
Périodique
Neuro-oncology
Auteur⸱e⸱s
Cicone F., Gnesin S., Santo G., Stokke C., Bartolomei M., Cascini G.L., Minniti G., Paganelli G., Verger A., Cremonesi M.
ISSN
1523-5866 (Electronic)
ISSN-L
1522-8517
Statut éditorial
In Press
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Résumé
Radiopharmaceutical theranostic treatments have grown exponentially worldwide, and internal dosimetry has attracted attention and resources. Despite some similarities with chemotherapy, radiopharmaceuticals treatments are essentially radiotherapy treatments, as the release of radiation into tissues is the determinant of the observed clinical effects. Therefore, absorbed dose calculations are key to explain dose-effect correlations and to individualize radiopharmaceutical treatments. The present article introduces the basic principles of internal dosimetry and provides an overview of available locoregional and systemic radiopharmaceutical treatments for CNS tumors. The specific characteristics of dosimetry as applied to these treatments are highlighted, along with their limitations and most relevant results. Dosimetry is performed with higher precision and better reproducibility than in the past, and dosimetric data should be systematically collected, as treatment planning and verification may help exploit the full potential of theranostic of CNS tumors.
Mots-clé
brain tumors, internal dosimetry, molecular radiotherapy, radionuclide therapy, theranostic
Pubmed
Création de la notice
04/10/2024 15:20
Dernière modification de la notice
05/10/2024 6:03
Données d'usage